Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
Erasca, Inc. (Nasdaq: ERAS), a precision oncology company focused on RAS/MAPK pathway-driven cancers, will participate in the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Jonathan E. Lim, M.D., CEO, and David M. Chacko, M.D., CFO, will engage in a "Fireside Chat" at 3:05 PM ET. Investors can register for the live webcast at Evercore.webcasts, with an archived replay available for 30 days on Erasca.com/events.
Erasca aims to develop innovative therapies targeting cancer pathways, leveraging expertise from top pioneers in the field.
- None.
- None.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Evercore ISI 4th Annual HealthCONx Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a “Fireside Chat” beginning at 3:05 PM Eastern Time on Thursday, December 2, 2021. The company will also participate in one-on-one investor meetings.
Registration and access to the live webcast is available at Evercore.webcasts. An archived replay of the event will be available at Erasca.com/events for 30 days following the webcast.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
When is Erasca participating in the Evercore ISI HealthCONx Conference?
Who will represent Erasca at the HealthCONx Conference?
What time is Erasca's Fireside Chat at the conference?
How can I access the Erasca webcast from the HealthCONx Conference?
Will there be a replay available for the Erasca webcast?
